Philip Storey is an Ophthalmology physician affiliated with Texas Retina Associates. OpenAlex indexes 96 publications with 1,870 citations (h-index 23).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
801 W 38th St Ste 200
Austin, TX 787051169
Telephone
512-451-0103Registry record last updated 8 Jul 2019.
Industry payments
20 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Regeneron Healthcare Solutions, Inc.Program year202520 payments$18,634openpaymentsdata.cms.gov ↗
- Genentech USA, Inc.Program year20254 payments
- Apellis Pharmaceuticals, Inc.Program year20255 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
59.8%Antineovascularisation agents41.5%Faricimab-svoa100%Part B, office-administered≥35 patientsComplement Inhibitor16.6%Avacincaptad pegol100%Part B, office-administered≥39 patients+ 5 more classes in this area
Cancer & immunology
39.5%Complement Inhibitor35.1%Pegcetacoplan100%Part B, office-administered≥65 patientsVascular Endothelial Growth Factor Inhibitor4.5%Aflibercept92%Bevacizumab8%Part B, office-administered≥135 patientsMusculoskeletal
0.3%Cyclooxygenase Inhibitor0.3%Ketorolac Tromethamine100%Part D≥44 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Endophthalmitis following cataract surgery: visual outcomes, microbial spectrum and complications
Current Opinion in Ophthalmology
2023 - Incidence and Visual Outcomes of Endophthalmitis After Intravitreal Injection of Dexamethasone Implant vs Ranibizumab
Journal of VitreoRetinal Diseases
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Kenneth Sall, MD
Texas Retina Associates
Rajiv Anand, MD
Texas Retina Associates
Ashkan Abbey, MD
Texas Retina Associates
Wayne Solley, MD
Texas Retina Associates
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”